Literature DB >> 17138829

Defective apoptosis of peripheral-blood lymphocytes in hyper-IgD and periodic fever syndrome.

Evelien J Bodar1, Jeroen C H van der Hilst, Waander van Heerde, Jos W M van der Meer, Joost P H Drenth, Anna Simon.   

Abstract

Hereditary periodic fever syndromes are characterized by incapacitating attacks of fever and generalized inflammation. While the mutated genes for the major syndromes in this group are known, the pathogenesis remains unclear. The aim of this study was to investigate apoptosis in patients with periodic fever as a possible pathogenic factor. We measured anisomycin-induced apoptosis with annexin-V flow cytometry and caspase-3/7 activity in peripheral-blood lymphocytes from symptom-free patients with hyper-IgD and periodic fever syndrome (HIDS; n = 10), TNF-receptor-associated periodic syndrome (TRAPS; n = 7), and familial Mediterranean fever (FMF; n = 2). HIDS lymphocytes showed a decreased percentage of apoptosis during remission by both methods compared with controls (17.8% vs 55.4%), whereas no difference was observed in TRAPS or FMF lymphocytes. This defective apoptosis of lymphocytes may be a central pathogenic mechanism in HIDS, since dysfunction of one of the inhibitory mechanisms to curtail the immunologic response could cause an unbridled generalized inflammation after a trivial stimulus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17138829     DOI: 10.1182/blood-2005-10-039578

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  The inhibition of mevalonate pathway induces upregulation of NALP3 expression: new insight in the pathogenesis of mevalonate kinase deficiency.

Authors:  Alessandra Pontillo; Elisa Paoluzzi; Sergio Crovella
Journal:  Eur J Hum Genet       Date:  2010-02-24       Impact factor: 4.246

2.  Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate.

Authors:  Giuseppe Lopalco; Donato Rigante; Antonio Vitale; Bruno Frediani; Florenzo Iannone; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2014-03-11       Impact factor: 2.980

Review 3.  Hyperimmunoglobulin D syndrome in childhood.

Authors:  Jeroen C H van der Hilst; Joost Frenkel
Journal:  Curr Rheumatol Rep       Date:  2010-04       Impact factor: 4.592

Review 4.  The spectrum of autoinflammatory diseases: recent bench to bedside observations.

Authors:  John G Ryan; Raphaela Goldbach-Mansky
Journal:  Curr Opin Rheumatol       Date:  2008-01       Impact factor: 5.006

Review 5.  Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*).

Authors:  Seth L Masters; Anna Simon; Ivona Aksentijevich; Daniel L Kastner
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

6.  Increased levels of circulating Annexin A5 in Familial Mediterranean fever.

Authors:  Anna S Boyajyan; Gohar M Mkrtchyan; Lilit P Hovhannisyan; Tigran J Hovsepyan
Journal:  J Inflamm (Lond)       Date:  2010-11-23       Impact factor: 4.981

7.  Enhanced blood lymphocytes apoptosis in children with inflammatory bowel disease.

Authors:  M A El-Hodhod; R H Aly; S R Youssef; S I Mohamed
Journal:  ISRN Gastroenterol       Date:  2013-08-29

8.  Abnormal IgD and IgA1 O-glycosylation in hyperimmunoglobulinaemia D and periodic fever syndrome.

Authors:  Jacob F de Wolff; Stephen J Dickinson; Alice C Smith; Karen Molyneux; John Feehally; Anna Simon; Jonathan Barratt
Journal:  Clin Exp Med       Date:  2009-06-20       Impact factor: 3.984

9.  A case of hyperimmunoglobulinemia d syndrome successfully treated with canakinumab.

Authors:  Elena Tsitsami; Charis Papadopoulou; Matthaios Speletas
Journal:  Case Rep Rheumatol       Date:  2013-04-16

Review 10.  Mevalonate kinase deficiency and neuroinflammation: balance between apoptosis and pyroptosis.

Authors:  Paola Maura Tricarico; Annalisa Marcuzzi; Elisa Piscianz; Lorenzo Monasta; Sergio Crovella; Giulio Kleiner
Journal:  Int J Mol Sci       Date:  2013-11-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.